natgillin/translations-raw huggingface dataset:
The method of claim 17, wherein the leukemia is chronic lymphocytic leukemia, chronic myelocytic leukemia, acute lymphoblastic leukemia or acute myeloid leukemia. 
Spoj za uporabu u skladu s patentnim zahtjevom 20, naznačen time što je leukemija kronična limfocitna leukemija, kronična mijelocitna leukemija, akutna limfoblastična leukemija ili akutna mijeloična leukemija.
Number of Pharmacokinetic Sampling 
(21) Broj predmeta:
transalification of heparin of an alkali or alkaline earth metal into benzalkonium heparinate; 
transalifikacije heparina alkalnih ili alkalija zemljanih metala u benzalkonij heparinat;
The combined organic phases were washed with water, dried over MgSO4, filtered and evaporated. 
Spojene organske faze se isperu s vodom, osuše preko MgSO,, filtriraju i upare.
The lipid particle of claim 7, wherein the particle further comprises a non-cationic lipid, preferably wherein the non-cationic lipid is selected from the group consisting of a phospholipid, cholesterol, or a mixture of a phospholipid and cholesterol, preferably wherein the phospholipid comprises dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), or a mixture thereof. 
Čestica lipida u skladu s patentnim zahtjevom 5, naznačena time, da čestica nadalje sadrži ne-kationski lipid, poželjno odabran iz skupine koja se sastoji od fosfolipida, kolesterola ili kolesterol derivata, ili smjese fosfolipida i kolesterola ili kolesterol derivata, pri čemu fosfolipid poželjno sadrži dipalmitoilfosfatidilkolin (DPPC), distearoilfosfatidil-kolin (DSPC), ili njihovu smjesu.
Structure Chemical Name 
Struktura Kemijski naziv 1
After stirring at 10 °C for 40 minutes, the resulting solution is treated dropwise with1-bromomethyl-4-methanesulfonyl-2-trifluoromethyl-benzene (23.8 g, 75.4 mmol) and allowed to warm to room temperature while stirring overnight. 
Nakon miješanja 40 minuta pri 10*C, dobivenu otopinu se pomiješa kap po kap s 1-brom-metil-4-metansulfonil-2-trifluormetil-benzenom (23,8 g, 75,4 mmolova) i pusti se zagrijati na sobnu temperaturu uz miješanje preko noći.
In another embodiment, the quenching agent is L-cysteine. In still another embodiment, the L-cysteine is added to result in a final concentration of about 10 mM and the conditions comprise a time period ofabout 60 minutes, a temperature of about 22oC, the absence of light and with stirring. 
Postupak prema zahtjevu 8, pri čemu je agens za gašenje L-cistein, i poželjno je dodan kako bi rezultirao krajnjom koncentracijom od oko 10 mM i uvjeti sadrže vremenski period od oko 60 minuta, temperaturu od oko 22 "€, odsutnost svjetla i s miješanjem.
and a pharmaceutical excipient. 
(b) farmaceutsku pomoćnu tvar,
Only metaphases containing 21±2 chromosomes were evaluated. 
Procjenjivane su samo metafaze koje sadrže 21 + 2 kromosoma.
The method according to Paragraph 43, in which the treatment elicits a partial response. The method according to Paragraph 43, in which the treatment elicits a minimal response. Use of an anti-CS1 antibody in the preparation of a first medicament and the use of lenalidomide in the preparation of a second medicament, said medicaments for use in the treatment of multiple myeloma, wherein the first medicament is administered concurrently, prior to or following the administration of the second medicament. 
UporabaHuL.uc63 za pripremu jednog prvog lijeka, pri čemu je taj HuL.uc63 humanizirano IgG1 antitijelo koje ima jednu varijabilnu regiju teškog lanca koja odgovara sekvenci SEQ ID NO:5 i jednu varijabilnu regiju lakog lanca koja odgovara sekvenci SEQ ID NO:6, te uporaba lenalidomida za pripremu jednog drugog lijeka, s time da se spomenuti lijekovi koriste za liječenje multiplog mijeloma, pri čemu se prvi lijek daje istovremeno, prije ili nakon davanja drugog lijeka.
The pharmaceutically-acceptable salt of claim 9, wherein the pharmaceutically acceptable salt is selected from the group consisting of acetate, ascorbate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, fumarate, hydrochloride, hydrobromide, hydroiodide, lactate, maleate, methanesulfonate, naphthalenesulfonate, nitrate, oxalate, phosphate, propionate, salicylate, succinate, sulfate, tartarate, thiocyanate, and toluenesulfonate. 
Kompozicija prema patentnom zahtjevu 18, naznačena time što je farmaceutski prihvatljiva sol izabrana iz grupe koja se sastoji od acetata, askorbata, benzoata, benzensulfonata, bisulfata, borata, butirata, citrata, kamforata, kamforsulfonata, fumarata, hidroklorida, hidrobromida, hidrojodida, laktata, maleata, metansulfonata, naftalensulfonata, nitrata, oksalata, fosfata, propionata, salicilata, sukcinata, sulfata, tartarata, tiocijanata i toluensulfonata.
a sequence having at least 85% identity with the sequence of SEQ ID NO.: 42 and comprising one or more transcription factor binding sites. 
(c) sekvencu koja obuhvaća barem 85% identiteta sekvence od SEQ ID NO:42 i sadrži jedno ili više mjesta spajanja faktora transkripcije.
When the reagent used is a carboxylic acid halide, an exemplary procedure (as shown in Figure 18) is as follows. 
Kada je reagens koji se koristi halogenid karboksilne kiseline, slijedi postupak koji je prikazan kao primjer (kao što je prikazano na slici 18).
column of the main frame 30 
stup glavnog okvira 30
The resulting solution was washed with water and saturated aqueous NaCl. 
Rezultirajuća otopina je isprana sa vodom i zasićenom vodenom otopinom NaCl.
A compound according to claim 1, wherein R1 is OR, where R is H, methyl, isopropyl or ethyl. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je R1 OR, gdje je R H, metil, izopropil ili etil.
A dispenser according to any preceding claim, wherein the limiting mechanism is supported on a base having a fixed end and a floating end, the fixed end being coupled to the limiting member and the floating end being free of the limiting member, and wherein the base is flexible at the fixed end such that the floating end is moveable radially with respect to the first ring member. 
Dispenzer u skladu sa bilo kojim od patentnih zahtjeva 18 do 22, gdje je mehanizam za ograničavanje (1606) podržan na osnovi koja ima fiksiran kraj i plutajući kraj, pri čemu je fiksirani kraj uparen za element (1602) za ograničavanje i plutajući element je slobodan od elementa za ograničavanje, i gdje je osnova savitljiva na fiksiranom kraju tako da plutajući kraj može da se pomiče radijalno u odnosu na prvi prstenasti element.
Cortexolone-17a-propionate in crystalline form III according to anyone of claims 1 to 3, for use in the treatment of pathologies affecting the urogenital system, the endocrine system, the skin, and/or the cutaneous appendages. 
Korteksolon-17a-propionat u kristalnom obliku I u skladu s bilo kojim od patentnih zahtjeva 17 do 18, naznačen time što je namijenjen upotrebi u liječenju patoloških pojava koje pogađaju urogenitalni sustav, endokrini sustav, kožu i/ili kožne adnekse.
The method of claim 18, wherein the additional therapeutic agent is an anti-HIV drug. 
Farmaceutska smjesa prema zahtjevu 16, gdje dodatno terapijsko sredstvo ima djelovanje protiv HIV-a.
Despite decades of interest and effort, there is still no fuel element comprising smoking article on the market which provides the benefits and advantages associated with conventional cigarette smoking, without delivering considerable quantities of incomplete combustion and pyrolysis products. 
I zaista, usprkos širokom interesiranju i naporima, još uvijek na tržištu ne postoji cigaretni substitut koji osigurava blagodati i prednosti koje pruža pušenje konvencionalnih cigareta, bez isporučivanja značajnih količina proizvoda nepotpunog izgaranja i pirolize.
determining a number of actual counts of the first allele based on the analysis of the plurality of nucleic acid molecules from the biological sample; and determining the fetal genome is heterozygous for the first allele and a second allele and the maternal genome is homozygous for the second allele when the number of actual counts is less than the cutoff value. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se određivanje prve skupine lokusa sastoji u tome što: za svakog od lokusa iz prve skupine: određivanje očinskog genoma je homozigotno za odgovarajući prvi alel; i određivanje majčinskog genoma je homozigotno za odgovarajući drugi alel.
A bispecific IgG antibody according to the invention, wherein said mutated CH2 and/or lower hinge domains comprise substitution L235G and/or G236R, is therefore also provided herein. Preferably, both L235G and G236R are substituted. 
Bispecifično IgG protutijelo sukladno patentnom zahtjevu 6 ili 7, naznačeno time što navedeni mutirani CH2 i/ili niže zglobne domene sadrže supstituciju L235G i/ili G236R, poželjno L235G i G236R.
The method of claim 11 or 12, whereby the reference setup stage includes an electrical interfacing stage including a combination of manually entering information into the device (10) and providing data sourced from the at least one current transformer electrical connectors connected to the electrical energy diagnostic device (10). 
Metoda prema zahtjevu 11 ili 12, pri čemu se unos referentnih podataka odnosi na fazu povezivanja koja pak uključuje kombinaciju ručnog unosa podataka u uređaj (10) 1 dobivanje podataka s najmanje jednog električnog konektora za strujne transformatore spojenog na navedeni uređaj (10).
The composition of claim 1, wherein R3 is selected from ethylenediamine and cyclohexanediamine. A composition for treating cancer, comprising: 
Pripravak za uporabu u postupku liječenja raka prema zahtjevu 1 naznačen time da je R* odabran od etilendiamina i cikloheksandiamina.
Unit Formula for Tablets (mg/tablet) 
[Jedinica formule za tablete (mg/tableta) eee eee
Preservatives mentioned in particular are p-hydroxybenzoic esters, benzyl alcohol, phenylmercury salts or chlorocresol. 
Od konzervansa treba posebno navesti estere p-hidroksibenzojeve kiseline, benzil alkohol, fenilmerkuri soli ili klorokrezol.
Likewise, molecules having a bond with restricted rotation may form geometric isomers. 
Također, molekule koje imaju vezu s ograničenom rotacijom mogu stvorili geometrijske izomere.
A crystalline structure of a compound of formula I in the form of its propylene glycol solvate. 
Kristalna struktura spoja s formulom I naznačena time da je u obliku njegovog propilen glikol solvata.
generating a wheel signal within a signal-processing unit if the shear stress difference signal exceeds a predetermined first upper limiting value or falls below a predetermined second lower limiting value. 
• generiranje signala kotača unutar jedinice za obradu signala kada diferencijalni signal smičnog naprezanja prekoračuje unaprijed određenu gornju graničnu vrijednost (G) ili prekoračuje unaprijed određenu donju graničnu vrijednost (G).
at least one nucleotide sequence coding for at least one protein toxin and/or at least one protein toxin subunit; and 
(ID) najmanje jedan nukleotidni odsječak koji kodira najmanje jedan proteinski toksin ifili najmanje jednu podjedinicu proteinskog toksina; i
Process according to claim 14 or 15, wherein the at least one solvent is selected from alcohols, ketones, esters and ethers, and preferably selected from isopropyl acetate and tert-butyl methyl ether. 
Postupak prema zahtjevu 14ili 15, naznačen time, da barem jedno otapalo je odabrano od alkohola, ketona, estera i etera, i poželjno je odabrano od izopropil acetata i tert-butil metiletera.
The drawing consists of the following figure: 
Broj objave europskog patenta:
Preferred saturated aliphatic monocarboxylic acids are formic acid, acetic acid or trifluoroacetic acid, more preferred being acetic acid in an amount of 791 to 1187 mol, most preferably 890 to 1088 mol, per 1 mol of 1-ethylcamptothecin. 
Poželjne zasićene alifatske monokarboksilne kiseline su mravlja, octena ili trifluoroctena kiselina, poželjnija je octena kiselina, u količini od 791 do 1187 mol, a najpoželjnije od 890 do 1088 mol, na 1 mol 1-etilkamptotecina.
Cortexolone-17a-propionate in crystalline form III according to anyone of claims 1 to 3, for use in the treatment of pathologies affecting the urogenital system, the endocrine system, the skin, and/or the cutaneous appendages. 
Korteksolon-17a-propionat u kristalnom obliku INI u skladu s bilo kojim od patentnih zahtjeva 15 do 18, naznačen time što je namijenjen upotrebi u liječenju patoloških pojava koje pogađaju urogenitalni sustav, endokrini sustav, kožu i/ili derivate kože.
The solution was refluxed overnight, cooled to room temperature and then stirred on an ice bath. 
Otopina je preko noći ostavljena u refluksu, ohlađena na sobnu temperaturu i polom miješana u ledenoj kupki.
Method in accordance with claim 1; characterised in that the step in which the flavouring agent is added includes a flavouring, selected from among kitchen salt, a sugar, a sweetener, butter. 
Postupak u skladu s patentnim zahtjevom 1; naznačen time što se sredstvo za aromatiziranje bira između kuhinjske soli, šećera, sladila i maslaca.
represents wherein * indicates the point of attachment of said group with the rest of the molecule; 
predstavlja: pri čemu * označava točku vezanja navedene skupine s ostatkom molekule;
The ice bath is removed, and the mixture is stirred at room temperature for about 18 h. 
Ledenu kupelj se ukloni, a smjesu miješa otprilike 18 sati na sobnoj temperaturi.
The combined aqueous extract was acidified with 6N hydrochloric acid to a pH of 6.5 and extracted again with ether (3 x 250 ml. 
Spojeni vodeni ekstrakt se zakiseli sa 6N klorovodičnom kiselinom do pH 6.5 1 ponovno se ekstrahira sa eterom (3 x 250 ml.
The garment according to claim 1, wherein said second elastic synthetic fibre material is elastane. 
Odjevni predmet, u skladu s patentnim zahtjevom 1, naznačen time, da je drugi elastični materijal od sintetičkih vlakana elastan.
A preferred, non-limiting embodiment of the invention will be described by way of example with reference to the accompanying drawings, in which: 
Pogodna, neograničavajuća izvedba izuma opisat će se putem primjera u odnosu na pridružene crteže, u kojima: Slika 1
mixing of the S-adenosyl methionine sulphate paratoluene sulphonate or S-adenosyl methionine-1,4-butane disulphonate with calcium oxide and pharmaceutically acceptable excipients, 
miješanja S-adenozilmetionin-sulfat-para-toluensulfonata ili S-adenozilmetionin-1,4-butan-disulfonata s kalcijevim oksidom i farmaceutski prihvatljivim pomoćnim tvarima,
anodization for preventing corrosion and scratches thereby increasing thermal conductivity; 
predviđena je anodna oksidacija kako bi se spriječilo koroziju i ogrebotine, pri čemu se povećava toplinska vodljivost;
The immunogenic composition of claims 1 to 11 or vaccine of claim 12 for use in the treatment or prevention of diseases caused by Streptococcus pneumoniae infection, wherein the disease is either or both of pneumonia or invasive pneumococcal disease (IPD) of elderly humans, exacerbations of chronic obstructive pulmonary disease (COPD) of elderly humans, otitis media of infant humans, meningitis and/or bacteraemia of infant humans, or pneumonia and/or conjunctivitis of infant humans. 
Imunogeni pripravak u skladu s patentnim zahtjevima 1-9 ili cjepivo u skladu s patentnim zahtjevom 10, naznačeni time što su namijenjeni upotrebi u liječenju ili sprječavanju bolesti uzrokovane infekcijom bakterijom Streptococcus pneumonijae u skladu s patentnim zahtjevom 12, gdje je bolest bilo pneumonija ili/i invazivna pneumokokna bolest (IPD) kod starijih ljudi, egzacerbacije kronična opstruktivne plućne bolesti (COPD) kod starijih ljudi, upala srednjeg uha kod ljudske dojenčadi, meningitis i/ili bakteriemija kod ljudske dojenčadi, ili pneumonija ifili konjunktivitis kod ljudske dojenčadi.
(c9) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 34; and (c10) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 171. 
(c9) L-lanac protutijela koji se sastoji od aminokiselinske sekvence SEQ ID NO: 34; i (c10) L-lanac protutijela koji se sastoji od aminokiselinske sekvence SEQ ID NO: 171.
The cracking furnace according to claim 11, wherein at least a number of the burners is positioned at the floor and/or the roof of the firebox and/or the side walls of the firebox and wherein the outlets of the coils extend through the roof of the firebox. 
Peć za cijepanje prema bilo kojem zahtjevu 7 do 12, naznačena time, da su barem neki od plamenika pozicionirani na podu i/ili na krovu gorive kutije i/ili na bočnim stijenkama kutije, i pri čemu se izlazi spirala protežu kroz krov gorive kutije.
The tablet according to claim 1 or 2, wherein per 1 part by weight of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, the tablet comprises: 
Tableta u skladu s patentnim zahtjevom 1 ili 2, naznačena time što na 1 težinski dio 7- [4- (4-benzo [b] tiofen-4-il-piperazin-1-il) butoksi] -1H-kinolin-2-on ili njegove soli, tableta sadrži:
in part (a), the heavy chain comprises a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:113 and/or the light chain comprises a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:112; 
3. - Protutijelo anti-FcRH5 prema zahtjevu 1 ili 2, naznačeno time, da protutijelo anti-FcRH5 obuhvaća sljedeće: (a) VH sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 113i VL sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 112;
The method of claim 1, wherein the systemic disease is chronic kidney disease. The method of claim 2, wherein the sartan is selected from the group consisting of irbesartan, losartan, and telmisartan. 
Sartan za uporabu prema zahtjevu 1, naznačen time, da je sartan odabran iz skupine koju čine: kandesartan, eprosartan, irbesartan, losartan, tazosartan, telmisartan, valsartan i njihova farmaceutski prihvatljiva sol.
The method of any of the preceding claims, wherein at least one of the following are computed from the packet header information extracted from the bit stream of the audio signal and/or derived from side information: at least a part of the coefficients, the bit rate, the average frame-loss rate Pfl, the average number of frames lost in a row µ. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se najmanje jedno od sljedećeg izračunava iz informacija iz zaglavlja paketa, izvađenih iz tijeka bitova audio signala i/ili izvedenih iz informacija HR P20131043 T1 sa strane: u najmanju ruku dio koeficijenata, brzina bita, prosječna stopa gubitka okvira Pfl, prosječan broj okvira izgubljenih u redu u.
The composition according to claim 1 for the use according to claim 1, wherein the nasal epithelium is the olfactory epithelium of the subject. 
Pripravak prema zahtjevu 1, naznačen time, da se upotrebljava u skladu s patentnim zahtjevom 1, naznačen time što je nazalni epitel subjekta olfaktorni epitel subjekta.
A cell comprising a polypeptide according to claim 1, a polynucleotide according to claim 2, a nucleic acid construct according to claim 3 or a vector according to claim 4, said cell is able to overexpress the polypeptide. 
Stanica koja sadrži polipeptid prema zahtjevu 1, polinukleotid prema zahtjevu 2, konstrukt nukleinske kiseline prema zahtjevu 3 ili vektor prema zahtjevu 4, naznačen time da je navedena stanica sposobna prekomjerno eksprimirati polipeptid.
VLP according to embodiment 1 or 2, whereas the drug delivery system crosses the blood-brain barrier to enter the CNS together with the drug encapsulated by the VLP. 
VLP za uporabu u skladu s patentnim zahtjevom 1 ili 2, dok VLP prelazi krvno-moždanu barijeru za ulazak u CNS zajedno s lijekom koji je enkapsuliran VILP-om.
Pharmaceutical composition according to one of the aspects 1 to 9, wherein the antibody or antigen-binding fragment thereof has one or more of the following features: 
Farmaceutski pripravak za uporabu u skladu s jednim od patentnih zahtjeva 1 do 4, naznačen time da protutijelo ili njegov fragment koji veže antigen ima jednu ili više od slijedećih značajki:
The method of claim 3, wherein the hydrogen donor is methanol, ethanol, propan-1-ol, propan-2-ol, butan-1-ol, butan-2-ol, cyclopentanol, cyclohexanol, benzylalcohol, a menthol, formic acid, lactic acid, ascorbic acid, mandelic acid, ammonium formate, potassium formate, cyclohexadiene, cyclohexene, 1-methylcyclohexene, tetralin, dihydrofuran, a terpene, diazene, hydrazine, hydroxylamine, or NaH2PO2, or a mixture thereof; or wherein the hydrogen donor is formic acid, ammonium formate, potassium formate, cyclohexene, 1-methylcyclohexene, NaH2PO2, or a mixture thereof; or wherein the hydrogen donor is a C1-14 carboxylic acid. 
Postupak u skladu s patentnim zahtjevom 3, naznačen time što je donor vodika metanol, etanol, propan-1-ol, propan-2-ol, butan-1-ol, butan-2-ol, ciklopentanol, cikloheksanol, benzilalkohol, mentol, mravlja kiselina, mliječna kiselina, askorbinska kiselina, bademova Kiselina, amonijev formijat, kalijev formijat, cikloheksadien, cikloheksen, 1-metilcikloheksen, tetralin, dihidrofuran, terpen, diazen, hidrazin, hidroksilamin ili NaH2PO2, ili njihova smjesa; ili gdje je donor vodika mravlja kiselina, amonijev formijat, kalijev formijat, cikloheksen, 1-metilcikloheksen, NaH2P02, ili njihova smjesa; ili gdje je donor vodika C1-14 karboksilna kiselina.
An isoquinoline-6-sulfonamide derivative represented by Formula (1), a salt thereof, or a solvate of the derivative or the salt: wherein 
Izokinolin-6-sulfonamid derivat predstavljen Formulom (1), sol istog ili solvat derivata ili sol:
In yet another embodiment, the programmable electrical control device includes an energy supply module for supplying electrical energy to any one or more of the data connection module, the memory, the timing module and the processor. 
Programabilni električni upravljački uređaj (10) sukladno bilo kojem zahtjeva 1 do 4, koji nadalje uključuje sinkronizator za usklađivanje modula za mjerenje vremena, pri čemu sinkronizator za sinkronizaciju po želji koristi napajanje električnom energijom.
The liquid composition of the present invention comprises: 
Datum podnošenja europske prijave patenta:
Protein concentrations are determined by standard spectrophotometric techniques. 
Protein koncentracije odredene su standardnim spektrofotometrijskim tehnikama.
in part (g), the heavy chain comprises a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:125 and/or the light chain comprises a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:124; 
VH sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 125 i VL sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 124;
The pharmaceutical composition of claim 16, in a topical dosage form. The pharmaceutical composition of claim 17, in a cream, a gel, or an ointment. A method of treating a disorder selected from the group consisting of human papilloma virus, cervical intraepithelial neoplasia, vulvar intraepithelial neoplasia, and anal intraepithelial neoplasia in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof. 
Spoj prema bilo kojem zahtjevu od 1 do 7 ili njegova farmaceutski prihvatljiva sol, za primjenu u liječenju virusnog oboljenja kod ispitanika, naznačen time, što je virusno oboljenje odabrano iz skupine koja se sastoji od ljudskog papilomavorusa, HIV-a, virusa hepatitisa B, virusa hepatitisa C, virusa boginja, virusa kravljih boginja, adenovirusa, citomegalovirusa, virusa herpesa simpleksa 1, virusa herpesa simpleksa 2, Epstein Barrovog virusa, BK virusa, JC virusa, cervikalne intraepitelne neoplazije, analne intraepitelne neoplazije i vulvarne intraepitelne neoplazije, virusa mačje leukemije i virusa mačje imunodeficijencije.
The composition of claim 1, further comprising an ascorbic acid ester or salt thereof. 
Pripravak iz patentnog zahtjeva 1, naznačen time, da dodatno sadrži ester askorbinske kiseline ili njezina sol.